Minodronate, a nitrogen-containing bisphosphonate, is a promising remedy for treating patients with diabetic retinopathy
- 1 January 2006
- journal article
- Published by Elsevier in Medical Hypotheses
- Vol. 66 (2) , 273-275
- https://doi.org/10.1016/j.mehy.2005.08.042
Abstract
No abstract availableKeywords
Funding Information
- Ministry of Education, Culture, Sports, Science and Technology
This publication has 17 references indexed in Scilit:
- Therapeutic Implications of Blockers of Advanced Glycation End Products (AGEs)-their Receptor (RAGE) SystemInternational Journal of Pharmacology, 2005
- Advanced Glycation End Products (AGEs) and Diabetic Vascular ComplicationsCurrent Diabetes Reviews, 2005
- Alternative routes for the formation of glyceraldehyde-derived AGEs (TAGE) in vivoMedical Hypotheses, 2004
- TAGE (toxic AGEs) hypothesis in various chronic diseasesMedical Hypotheses, 2004
- Regulation of Human Melanoma Growth and Metastasis by AGE–AGE Receptor InteractionsJournal of Investigative Dermatology, 2004
- Angiogenesis induced by advanced glycation end products and its prevention by cerivastatinThe FASEB Journal, 2002
- Advanced Glycation End Products-Induced Apoptosis and Overexpression of Vascular Endothelial Growth Factor in Bovine Retinal PericytesBiochemical and Biophysical Research Communications, 2002
- Pyridoxamine, an Inhibitor of Advanced Glycation Reactions, Also Inhibits Advanced Lipoxidation ReactionsPublished by Elsevier ,2000
- Farnesyl Pyrophosphate Synthase Is the Molecular Target of Nitrogen-Containing BisphosphonatesBiochemical and Biophysical Research Communications, 1999
- Accumulation of Bisphosphonates in Human Artery and their Effects on Human and Rat Arterial Functionin vitroBasic & Clinical Pharmacology & Toxicology, 1998